Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis
Open accessThe DOI matches its Crossref record; 54 of the 56 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis is a complex autoimmune disease, and several therapies for multiple sclerosis have been developed and widely used. However, existing medications for multiple sclerosis were far from satisfactory due to their failure to suppress relapses and alleviate disease progression. Novel drug targets for multiple sclerosis prevention are still needed. We performed Mendelian randomization to explore potential drug targets for multiple sclerosis using summary statistics from the International Multiple Sclerosis Genetics Consortium (nCase = 47 429, nControl = 68 374) and further replicated in UK Biobank (nCase = 1356, nControl = 395 209) and FinnGen cohorts (nCase = 1326, nControl = 359 815). Genetic instruments for 734 plasma and 154 CSF proteins were obtained from recently published genome-wide association studies. The reverse causality detection using bidirectional Mendelian randomization analysis and Steiger filtering, Bayesian co-localization, and phenotype scanning that searched previously reported genetic variant–trait associations were implemented to consolidate the Mendelian randomization findings further. In addition, the protein–protein interaction network was performed to reveal potential associations among proteins and/or present multiple sclerosis medications. At Bonferroni significance (P < 5.63 × 10−5), Mendelian randomization analysis revealed six protein–multiple sclerosis pairs. In plasma, per standard deviation increase in FCRL3, TYMP and AHSG had a protective effect. Odds ratios for the proteins above were 0.83 (95% CI, 0.79–0.89), 0.59 (95% CI, 0.48–0.71) and 0.88 (95% CI, 0.83–0.94), respectively. In CSF, per 10-fold increase in MMEL1 (OR, 5.03; 95% CI, 3.42–7.41) increased the risk of multiple sclerosis, while SLAMF7 (OR, 0.42; 95% CI, 0.29–0.60) and CD5L (OR, 0.30; 95%CI, 0.18–0.52) decreased the risk. None of the six proteins had reverse causality. Bayesian co-localization suggested that FCRL3 [coloc.abf-posterior probability of hypothesis 4 (PPH4) = 0.889], TYMP (coloc.susie-PPH4 = 0.896), AHSG (coloc.abf-PPH4 = 0.957, coloc.susie-PPH4 = 0.973), MMEL1 (coloc.abf-PPH4 = 0.930) and SLAMF7 (coloc.abf-PPH4 = 0.947) shared the same variant with multiple sclerosis. FCRL3, TYMP and SLAMF7 interacted with target proteins of current multiple sclerosis medications. MMEL1 was replicated in both UK Biobank and FinnGen cohorts. Our integrative analysis suggested that genetically determined levels of circulating FCRL3, TYMP, AHSG, CSF MMEL1 and SLAMF7 had causal effects on multiple sclerosis risk. These findings suggested those five proteins might be promising drug targets for multiple sclerosis and warrant further clinical investigation, especially FCRL3 and SLAMF7.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MR uses genetic variants as instrumental variables, providing robust causal inference and offering insight into the biological pathways driving disease progression [16,17].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749 · cited 1×
“28 In addition, we conducted MR by Wald ratio method and Bayesian co-localization by coloc.abf algorithm with prioritized proteins as both exposure and outcome.”
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 7×
“Finally, using the GWAS data from the UK Biobank 13 and FinnGen 14 cohorts and plasma pQTL data from two newly published studies, 15,16 we replicated the analysis as an exter-nal validation to strengthen our conclusion.”
InfluentialDrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · cited 1×
“27 We also searched current medications targeting the identified potential causal proteins.”
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
Davey Smith, G., & Hemani, G. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu328 · Cited by 4,677 · cited 1×
“23 Complete summary statistics for proteins were obtained from three previous studies.”
Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., & Plagnol, V. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004383 · Cited by 4,261 · cited 1×
“…for posterior probability, five proteins identified by MR (FCRL3, TYMP, AHSG, MMEL1 and SLAMF7) were likely to share the same variant of MS. 33 Four of the five identified proteins (FCRL3, TYMP, AHSG and MMEL1) were found to be associated with other traits via phenotype scanning, but none…”
Orienting the causal relationship between imprecisely measured traits using GWAS summary data.
Hemani, G., Tilling, K., & Davey Smith, G. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007081 · Cited by 2,607 · cited 1×
“We also conducted Steiger filtering to ensure the directionality of the association between proteins and MS. 24 The results were considered statistically significant at P < 0.05.”
InfluentialGenomic atlas of the human plasma proteome
Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., Burgess, S., Jiang, T., Paige, E., Surendran, P., et al. (2018) · Nature · doi:10.1038/s41586-018-0175-2 · Cited by 2,268 · cited 2×
“12,16,18 The effect was estimated using MR-IVW, MR-Egger, weighted median, simple mode and weighted mode.”
PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations
Kamat, M. A., Blackshaw, J. A., Young, R., Surendran, P., Burgess, S., Danesh, J., Butterworth, A. S., & Staley, J. R. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz469 · Cited by 2,155 · cited 1×
“Phenotype scanning was conducted via both ‘phe-noscanner’ 26 and looking up in the study of Ferkingstad et al .”
Dobson, R., & Giovannoni, G. (2019) · European Journal of Neurology · doi:10.1111/ene.13819 · Cited by 2,148
Guidelines for performing Mendelian randomization investigations
Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.1 · Cited by 1,834
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium, Patsopoulos, N. A., Baranzini, S. E., Santaniello, A., Shoostari, P., Cotsapas, C., Wong, G., Beecham, A. H., James, T., Replogle, J., et al. (2019) · Science · doi:10.1126/science.aav7188 · Cited by 1,818
Large-scale integration of the plasma proteome with genetics and disease
Ferkingstad, E., Sulem, P., Atlason, B. A., Sveinbjornsson, G., Magnusson, M. I., Styrmisdottir, E. L., Gunnarsdottir, K., Helgason, A., Oddsson, A., Halldorsson, B. V., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00978-w · Cited by 1,697 · cited 6×
“16 a plasma proteome GWAS.”
InfluentialThe support of human genetic evidence for approved drug indications
Nelson, M. R., Tipney, H., Painter, J. L., Shen, J., Nicoletti, P., Shen, Y., Floratos, A., Sham, P. C., Li, M. J., Wang, J., et al. (2015) · Nature Genetics · doi:10.1038/ng.3314 · Cited by 1,666 · cited 2×
“…and per 10-fold increase in CSF protein levels. which used the pQTL in the plasma and CSF, this study used the blood expression and methylation QTL. Owing to the importance of protein drug targets for the success of market approval, 6,7 our study is a key addition to the research by Jacobs et al .”
Zhou, W., Nielsen, J. B., Fritsche, L. G., Dey, R., Gabrielsen, M. E., Wolford, B. N., LeFaive, J., VandeHaar, P., Gagliano, S. A., Gifford, A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0184-y · Cited by 1,544
Guidelines for performing Mendelian randomization investigations
Burgess, S., Davey Smith, G., Davies, N. M., Dudbridge, F., Gill, D., Glymour, M. M., Hartwig, F. P., Holmes, M. V., Minelli, C., Relton, C. L., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15555.2 · Cited by 1,273 · cited 1×
“22,25”
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205 · cited 2×
“In addition, to explore the interactions between those MS-associated genes and the targets for medications already on the market, we obtained 13 disease-modifying drugs for MS from a recent review 4 and corresponding drug targets based on the Drugbank database (https://www.drugbank.ca).”
Vimaleswaran, K. S., Berry, D. J., Lu, C., Tikkanen, E., Pilz, S., Hiraki, L. T., Cooper, J. D., Dastani, Z., Li, R., Houston, D. K., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001383 · Cited by 1,046 · cited 1×
“31 To limit the bias from horizontal pleiotropy, we only used cis -pQTLs as the instruments, given their direct role in the transcription and/or translation of Potential drug targets for MS BRAIN 2023: 146; 3364–3372 | 3367 related genes.”
Zheng, J., Haberland, V., Baird, D., Walker, V., Haycock, P., Hurle, M., Gutteridge, A., Erola, P., Liu, Y., Luo, S., et al. (2019) · doi:10.1101/627398 · Cited by 812 · cited 6×
“30 A ‘causality’ identified by MR might be reverse causality, horizontal pleiotropy or genetic confounding due to LD. 6 Hence, bi-directional MR was conducted in the study and no proteins identified by the primary MR analysis showed reverse causality, which was further supported by Steiger…”
InfluentialConnecting genetic risk to disease end points through the human blood plasma proteome
Suhre, K., Arnold, M., Bhagwat, A. M., Cotton, R. J., Engelke, R., Raffler, J., Sarwath, H., Thareja, G., Wahl, A., DeLisle, R. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14357 · Cited by 800
Co-regulatory networks of human serum proteins link genetics to disease
Emilsson, V., Ilkov, M., Lamb, J. R., Finkel, N., Gudmundsson, E. F., Pitts, R., Hoover, H., Gudmundsdottir, V., Horman, S. R., Aspelund, T., et al. (2018) · Science · doi:10.1126/science.aaq1327 · Cited by 680
VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown
Argaw, A. T., Gurfein, B. T., Zhang, Y., Zameer, A., & John, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808698106 · Cited by 666 · cited 1×
“51,52 Together, TYMP might be a potential therapeutic target for MS, and current floxuridine targeting might affect MS. SLAMF7 is a cell-surface receptor protein selectively expressed on natural killer cells leading to antibody-dependent cellular cytotoxicity and direct natural killer cell…”
Mapping the proteo-genomic convergence of human diseases
Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Cortes, A., Koprulu, M., Wörheide, M. A., Oerton, E., Cook, J., Stewart, I. D., Kerrison, N. D., et al. (2021) · Science · doi:10.1126/science.abj1541 · Cited by 657 · cited 3×
“15 (4775 plasma proteins measured in 10 708 participants) and Ferkingstad et al .”
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573 · cited 1×
“38 Considering the pathogenesis of PMS, which is characterized by chronic inflammation compartmentalized behind a closed blood–brain barrier, 3 we explored the causal proteins for MS not only in the plasma but also in the CSF and compared their effects thereafter.”
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459 · cited 2×
“3 Disease-modifying therapy is an integral part of MS management, which can reduce relapse occurrence and slow progression to permanent disability in patients with MS.”
Yao, C., Chen, G., Song, C., Keefe, J., Mendelson, M., Huan, T., Sun, B. B., Laser, A., Maranville, J. C., Wu, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05512-x · Cited by 431
Wingo, A. P., Liu, Y., Gerasimov, E. S., Gockley, J., Logsdon, B. A., Duong, D. M., Dammer, E. B., Robins, C., Beach, T. G., Reiman, E. M., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00773-z · Cited by 366 · cited 1×
“9,10 However, to date, few MR studies integrating GWAS and protein quantitative trait loci (pQTL) data on MS have been reported.”
Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease
Folkersen, L., Fauman, E., Sabater-Lleal, M., Strawbridge, R. J., Frånberg, M., Sennblad, B., Baldassarre, D., Veglia, F., Humphries, S. E., Rauramaa, R., et al. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006706 · Cited by 343 · cited 2×
“As described previously, 21 Bayesian co-localization provides the posterior probability for five hypotheses on whether a single variant is shared between two traits.”
Yang, C., Farias, F. H. G., Ibanez, L., Suhy, A., Sadler, B., Fernandez, M. V., Wang, F., Bradley, J. L., Eiffert, B., Bahena, J. A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00886-6 · Cited by 290 · cited 3×
“CSF pQTL data were obtained from a study by Yang et al ., 12 who re-ported 274 pQTLs of 184 CSF proteins.”
Advancing the use of genome-wide association studies for drug repurposing
Reay, W. R., & Cairns, M. J. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00387-z · Cited by 283 · cited 1×
“8 MR is a genetic instrumental variable analysis that usually utilizes single nucleotide polymorphisms (SNPs) from genome-wide association studies (GWAS) as genetic instruments to estimate the causal effect of an exposure on an outcome.”
Chapouly, C., Tadesse Argaw, A., Horng, S., Castro, K., Zhang, J., Asp, L., Loo, H., Laitman, B. M., Mariani, J. N., Straus Farber, R., et al. (2015) · Brain · doi:10.1093/brain/awv077 · Cited by 190 · cited 1×
“51,52 Together, TYMP might be a potential therapeutic target for MS, and current floxuridine targeting might affect MS. SLAMF7 is a cell-surface receptor protein selectively expressed on natural killer cells leading to antibody-dependent cellular cytotoxicity and direct natural killer cell…”
From expression QTLs to personalized transcriptomics
Montgomery, S. B., & Dermitzakis, E. T. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2969 · Cited by 189 · cited 1×
“32 In addition, Bayesian co-localization was also used to exclude the bias introduced by LD.”
Chong, M., Sjaarda, J., Pigeyre, M., Mohammadi-Shemirani, P., Lali, R., Shoamanesh, A., Gerstein, H. C., & Paré, G. (2019) · Circulation · doi:10.1161/circulationaha.119.040180 · Cited by 173 · cited 1×
“9,10 However, to date, few MR studies integrating GWAS and protein quantitative trait loci (pQTL) data on MS have been reported.”
Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers
Ottervald, J., Franzén, B., Nilsson, K. C., Andersson, L. I., Khademi, M., Eriksson, B., Kjellström, S., Marko‐Varga, G., Végvári, Á., Harris, R. A., et al. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.01.004 · Cited by 151 · cited 1×
“45 48 Although the different expression patterns of AHSG due to tissue specificity might account for this discrepancy, AHSG was the only protein that was validated by both co-localization meth-ods, indicating a higher probability of AHSG being a causal protein for MS. Future studies are warranted…”
Deng, Y., Ou, Y., Wu, B., Yang, Y., Jiang, Y., Huang, Y., Liu, Y., Tan, L., Dong, Q., Suckling, J., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01507-9 · Cited by 147 · cited 1×
“22,25”
Cladribine: mechanisms and mysteries in multiple sclerosis
Jacobs, B. M., Ammoscato, F., Giovannoni, G., Baker, D., & Schmierer, K. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-317411 · Cited by 98 · cited 1×
“…RRM2B, the targets of cladribine, suggesting that TYMP might act by inhibiting DNA synthesis and repair, mainly in lymphocytes, to influence MS. 49,50 Notably, TYMP is also an astrocyte-derived blood–brain barrier permeability modulator that interacts with VEGFA, another blood–brain barrier…”
FCRL 3 promotes TLR 9‐induced B‐cell activation and suppresses plasma cell differentiation
Li, F. J., Schreeder, D. M., Li, R., Wu, J., & Davis, R. S. (2013) · European Journal of Immunology · doi:10.1002/eji.201243068 · Cited by 84 · cited 2×
“40,41 Consistent with our results, previous genetic studies have reported that the high producer variant of the FCRL3 gene protected against MS in Spanish and Chinese populations.”
Human Fc Receptor-like 3 Inhibits Regulatory T Cell Function and Binds Secretory IgA
Agarwal, S., Kraus, Z., Dement-Brown, J., Alabi, O., Starost, K. A., & Tolnay, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.099 · Cited by 75 · cited 1×
“40,41 Consistent with our results, previous genetic studies have reported that the high producer variant of the FCRL3 gene protected against MS in Spanish and Chinese populations.”
Thymidine phosphorylase: A potential new target for treating cardiovascular disease
Li, W., & Yue, H. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.10.003 · Cited by 73 · cited 1×
“…and RRM2B, the targets of cladribine, suggesting that TYMP might act by inhibiting DNA synthesis and repair, mainly in lymphocytes, to influence MS. 49,50 Notably, TYMP is also an astrocyte-derived blood–brain barrier permeability modulator that interacts with VEGFA, another blood–brain barrier…”
Diagnosis and Management of Progressive Multiple Sclerosis
Macaron, G., & Ontaneda, D. (2019) · Biomedicines · doi:10.3390/biomedicines7030056 · Cited by 70 · cited 1×
“4 However, most of these medications target the inflammatory component of the disease and mainly affect RRMS, 5 while treatment of PMS remains unsatisfactory.”
Type 1 diabetes mellitus and multiple sclerosis: common etiological features
Handel, A. E., Handunnetthi, L., Ebers, G. C., & Ramagopalan, S. V. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.216 · Cited by 60 · cited 1×
“Phenoscanner also revealed associations be-tween SNP and several autoimmune diseases, while co-occurrence of MS and type 1 diabetes, 34 primary sclerosing cholangitis 35 and rheumatoid arthritis 36 has been reported previously, suggesting a common aetiology of the aforementioned diseases.”
Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis
Harris, V., Donelan, N. R., Yan, Q. J., Clark, K., Touray, A., Rammal, M., & Sadiq, S. A. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458513477923 · Cited by 59
Effects of fetuin-A with diverse functions and multiple mechanisms on human health
İçer, M. A., & Yıldıran, H. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.11.004 · Cited by 56 · cited 1×
“45 48 Although the different expression patterns of AHSG due to tissue specificity might account for this discrepancy, AHSG was the only protein that was validated by both co-localization meth-ods, indicating a higher probability of AHSG being a causal protein for MS. Future studies are warranted…”
Jacobs, B. M., Taylor, T. R., Awad, A. M. M., Baker, D., Giovanonni, G., Noyce, A. J., & Dobson, R. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa119 · Cited by 52 · cited 2×
“39 Unlike our study, Odds ratios for increased risk of MS were expressed as per SD increase in plasma protein levels and per 10-fold increase in CSF protein levels. which used the pQTL in the plasma and CSF, this study used the blood expression and methylation QTL. Owing to the importance of…”
Toussirot, É., Pertuiset, É., Martin, A., Melac-Ducamp, S., Alcalay, M., Grardel, B., Seror, P., Perdriger, A., Wendling, D., Mulleman, D., et al. (2006) · PubMed · Cited by 45
Matesanz, F., Fernández, Ó., Milne, R. L., Fedetz, M., Leyva, L., Guerrero, M., Delgado, C., Lucas, M., Izquierdo, G., & Alcina, A. (2008) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.01.004 · Cited by 43 · cited 1×
“42,43 Besides, we found a suggestive linkage between the pQTLs of FCRL3 (rs7528684) and CD5L (rs6427401) (LD r 2 = 0.65).”
InfluentialMcGowan, L. M., Davey Smith, G., Gaunt, T. R., & Richardson, T. G. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz155 · Cited by 38 · cited 1×
“30 A ‘causality’ identified by MR might be reverse causality, horizontal pleiotropy or genetic confounding due to LD. 6 Hence, bi-directional MR was conducted in the study and no proteins identified by the primary MR analysis showed reverse causality, which was further supported by Steiger…”
Bri2-23 is a potential cerebrospinal fluid biomarker in multiple sclerosis
Harris, V., Diamanduros, A., Good, P., Zakin, E., Chalivendra, V., & Sadiq, S. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.06.007 · Cited by 35
Specific hypomethylation programs underpin B cell activation in early multiple sclerosis
Ma, Q., Caillier, S. J., Muzic, S. I., Wilson, M. R., Henry, R. G., Cree, B., Hauser, S. L., Didonna, A., Oksenberg, J. R., Alexander, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111920118 · Cited by 35 · cited 1×
“…study also observed that the methylation of SLAMF7 was upregulated in B cells of patients with MS, suggesting the association of SLAMF7 with MS. 54 Different from the three identified MS targets in this study, the therapeutic agent targeting SLAMF7 has been well developed and evaluated in…”
Ban, M., McCauley, J. L., Zuvich, R. L., Baker, A., Bergamaschi, L., Cox, M., Kemppinen, A., D’Alfonso, S., Guerini, F. R., Lechner‐Scott, J., et al. (2010) · Genes and Immunity · doi:10.1038/gene.2010.36 · Cited by 34 · cited 2×
“Similar to our results, a previous GWAS study suggested that MMEL1 is a susceptibility gene for MS. 44 Although we did not find that MMEL1 interacted with the target for current MS medications by PPI analysis, it was the only biomarker that was externally validated in both the UK Biobank and…”
Elotuzumab: First Global Approval
Markham, A. (2016) · Drugs · doi:10.1007/s40265-016-0540-0 · Cited by 34 · cited 2×
“53 Consistent with our results, a recent genetic study also observed that the methylation of SLAMF7 was upregulated in B cells of patients with MS, suggesting the association of SLAMF7 with MS. 54 Different from the three identified MS targets in this study, the therapeutic agent targeting SLAMF7…”
Yuan, M., Wei, L., Zhou, R., Bai, Q., Wei, Y., Zhang, W., & Huang, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9149-7 · Cited by 21 · cited 1×
“42,43 Besides, we found a suggestive linkage between the pQTLs of FCRL3 (rs7528684) and CD5L (rs6427401) (LD r 2 = 0.65).”
InfluentialElevated fibrinogen levels in neuromyelitis optica is associated with severity of disease
Zhang, Y., Zhang, X., Liu, D., Wang, H., Pan, S., Wang, D., & Chen, X. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2628-4 · Cited by 16 · cited 1×
“37 Therefore, FCRL3, TYMP, AHSG, MMEL1 and SLAMF7 might be potential drug targets for MS, but the role of AHSG should be care-fully interpreted.”
Zhang, Y., Xu, Y., Xu, T., Yin, H., Zhu, Y., Peng, B., & Cui, L. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102461 · Cited by 15
Self-citationConcurrence of multiple sclerosis and primary biliary cholangitis: Report of 3 cases.
Sattar, M., & Poursadeghfard, M. (2020) · PubMed · doi:10.22088/cjim.11.2.223 · Cited by 6 · cited 1×
“Phenoscanner also revealed associations be-tween SNP and several autoimmune diseases, while co-occurrence of MS and type 1 diabetes, 34 primary sclerosing cholangitis 35 and rheumatoid arthritis 36 has been reported previously, suggesting a common aetiology of the aforementioned diseases.”
Cited by
Åkesson, J., Hojjati, S., Hellberg, S., Raffetseder, J., Khademi, M., Rynkowski, R., Kockum, I. S., Altafini, C., Lubovac-Pilav, Z., Mellergård, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42682-9 · Cited by 116
Does co-localization analysis reinforce the results of Mendelian randomization?
Yin, Q., & Zhu, L. (2023) · Brain · doi:10.1093/brain/awad295 · Cited by 70
Zou, X., Wang, L., Wang, S., Zhang, Y., Ma, J., Chen, L., Li, Y., Yao, T., Zhou, H., Wu, L., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000922 · Cited by 37
“…(such as proteomics) and outcome (IS) in a genetic context and excludes the in fl uence of confounding factors on causality with the aid of multiple sensitivity analyses [9] , and the exclusion of potential confounding factors is one of its advantages over traditional observational studies [10] .”
BackgroundMethodInfluentialProteome-wide mendelian randomization study implicates therapeutic targets in common cancers
Ren, F., Jin, Q., Liu, T., Xuelei, R., & Zhan, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04525-5 · Cited by 40
“…cancer; CCa: colorectal cancer; BLCa: bladder cancer; OCa: ovarian cancer; KCa: kidney cancer; GCa: gastric cancer; cis-pQTL: cis-protein quantitative trait loci; PPH4: posterior probability of hypothesis 4 variation strategy, which utilized genome-wide significant SNPs as genetic instruments [28].”
BackgroundQiu, X., Guo, R., Wang, Y., Zheng, S., Wang, B., & Gong, Y. (2024) · Communications Biology · doi:10.1038/s42003-024-06755-9 · Cited by 24
“…MR (SMR) and two-sample MR (TSMR) enable to estimate pleiotropic or potentially causal associations between genetically determined traits (e.g., gene expression, DNA methylation and protein expression) and complex traits of interest (disease phenotypes as outcomes, e.g., tumors) 16 – 19 .”
Metadata
- Authors
- Lin, J., Zhou, J., & Xu, Y.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Xu, Yan
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-02
- Volume
- 146
- Issue
- 8
- Pages
- 3364-3372
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC10393411
- OpenAlex
- W4323035146
- Cited by
- 271
- References
- 56
- Citations by year
- 2026: 43 · 2025: 87 · 2024: 120 · 2023: 21
- FWCI
- 55.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Peking Union Medical College Deposition Research Fund (ZC201904188)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Mapping and Diversity in Plants and Animals
- Keywords
- multiple sclerosis, therapeutic target, plasma proteins, cerebrospinal fluid protein, FCRL3, SLAMF7, CD5L, fetuin-A, thymidine phosphorylase, reverse causality, protein-protein interaction network, autoimmune disease, genetic risk factors, disease progression, relapse prevention, neuroinflammation, neurodegeneration
- MeSH terms
- Bayes Theorem, Humans, Multiple Sclerosis, Phenotype, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.